{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:57:04Z","timestamp":1785445024248,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.breast.2025.104458","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T21:47:57Z","timestamp":1742680077000},"page":"104458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk"],"prefix":"10.1016","volume":"81","author":[{"given":"Volkmar","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"H\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Thill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Banys-Paluchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Schmatloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4885-8471","authenticated-orcid":false,"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Langanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Uhrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"H\u00e4berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja N.","family":"Fehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00eb","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Terhaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Heilenk\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rudlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wuerstlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Aydogdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon-Denise","family":"Keyver-Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Hammerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalija","family":"Deuerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Stickeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahriye","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Belleville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Ditsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Baila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Iuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Y.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas D.","family":"Hartkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.breast.2025.104458_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s10549-011-1872-9","article-title":"Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer","volume":"131","author":"Collins","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.breast.2025.104458_bib2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/a-2073-1887","article-title":"Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer - controversies and standards in healthcare","volume":"83","author":"Muller","year":"2023","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"18","key":"10.1016\/j.breast.2025.104458_bib3","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2001.19.18.3817","article-title":"Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer","volume":"19","author":"Goldhirsch","year":"2001","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2025.104458_bib4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdi326","article-title":"Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005","volume":"16","author":"Goldhirsch","year":"2005","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2025.104458_bib5","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/bjc.2016.359","article-title":"The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients","volume":"115","author":"Lambertini","year":"2016","journal-title":"Br J Cancer"},{"issue":"25","key":"10.1016\/j.breast.2025.104458_bib6","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.breast.2025.104458_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104458_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2025.104458_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.hoc.2022.08.006","article-title":"Role of ovarian suppression in early premenopausal breast cancer","volume":"37","author":"Francis","year":"2023","journal-title":"Hematol Oncol Clin N Am"},{"issue":"36","key":"10.1016\/j.breast.2025.104458_bib10","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1200\/JCO.2006.07.2793","article-title":"Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer","volume":"24","author":"Walshe","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2025.104458_bib11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0959-8049(97)10036-3","article-title":"Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI","volume":"34","author":"Pagani","year":"1998","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2025.104458_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000524879","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2022","volume":"17","author":"Ditsch","year":"2022","journal-title":"Breast Care"},{"issue":"9","key":"10.1016\/j.breast.2025.104458_bib14","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2025.104458_bib15","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2025.104458_bib16","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","article-title":"Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009","volume":"20","author":"Goldhirsch","year":"2009","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.breast.2025.104458_bib17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","article-title":"Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007","volume":"18","author":"Goldhirsch","year":"2007","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.breast.2025.104458_bib18","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2003.04.576","article-title":"Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer","volume":"21","author":"Goldhirsch","year":"2003","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.breast.2025.104458_bib19","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2011.36.4950","article-title":"American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer","volume":"29","author":"Griggs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104458_bib20","series-title":"San antonio breast cancer symposium 2021","first-page":"GS2","article-title":"Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: a patient level meta-analysis of 7,030 women in four randomised trials","author":"Bradley","year":"2021"},{"issue":"3","key":"10.1016\/j.breast.2025.104458_bib21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.104458_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231151840","article-title":"Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer","volume":"15","author":"Paluch-Shimon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2025.104458_bib23","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","author":"Hortobagyi","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2025.104458_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl_5","key":"10.1016\/j.breast.2025.104458_bib25","first-page":"S407","article-title":"Adjuvant endocrine therapy combined with abemaciclib in monarchE patients with high-risk early breast cancer: disease characteristics and endocrine therapy choice by menopausal status","volume":"32","author":"Paluch-Shimon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104458_bib26","series-title":"Premenopausal endocrine responsive chemotherapy trial (PERCHE)","year":"2003"},{"key":"10.1016\/j.breast.2025.104458_bib27","series-title":"Triptorelin with either exemestane or tamoxifen in treating premenopausal women with hormone-responsive breast cancer (TEXT)","year":"2003"},{"issue":"7","key":"10.1016\/j.breast.2025.104458_bib28","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2025.104458_bib29","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.22.01065","article-title":"Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT","volume":"41","author":"Francis","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104458_bib30","series-title":"Tamoxifen versus anastrozole, alone or in combination with zoledronic acid","year":"2006"},{"key":"10.1016\/j.breast.2025.104458_bib31","series-title":"HOBOE: a phase 3 study of adjuvant triptorelin and tamoxifen, letrozole, or letrozole and zoledronic acid in premenopausal patients with breast cancer. (HOBOE)","year":"2006"},{"issue":"11","key":"10.1016\/j.breast.2025.104458_bib32","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdz298","article-title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","volume":"30","author":"Ferreira","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104458_bib33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000516419","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2021","volume":"16","author":"Ditsch","year":"2021","journal-title":"Breast Care"},{"issue":"4","key":"10.1016\/j.breast.2025.104458_bib34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000501000","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2019","volume":"14","author":"Ditsch","year":"2019","journal-title":"Breast Care"},{"issue":"6","key":"10.1016\/j.breast.2025.104458_bib38","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104458_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2025.104458_bib40","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.104458_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114239","article-title":"Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos\/HER2neg breast cancer patients treated with upfront letrozole","volume":"209","author":"Fasching","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625004758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625004758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T02:53:22Z","timestamp":1763607202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625004758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":37,"alternative-id":["S0960977625004758"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104458","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104458"}}